FDA Brief

Warning letters Food

FDA warning letter to

Chambers' Apothecary

LowIssued Nov 14, 2022Posted Nov 17, 2022Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Chambers' Apothecary that website claims make Blood Pressure Support and CoEnzyme Q10 unapproved new drugs.

What happened

FDA reviewed www.chambersapothecary.com in October 2022 and found order pages for Blood Pressure Support and CoEnzyme Q10 with claims that the products lower blood pressure, lower cholesterol, or improve heart disease. FDA said these claims make the products drugs intended to treat disease, but they are not FDA-approved and lack adequate directions for use.

What FDA found

  1. FDA said the website claims show Blood Pressure Support and CoEnzyme Q10 are intended to cure, mitigate, treat, or prevent disease, which makes them drugs.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]
  2. FDA said the products are new drugs because they are not generally recognized as safe and effective for the claimed uses and have no FDA approval.

    section 201(p) [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. FDA said the products are misbranded because they do not bear adequate directions for a layperson to use them safely for their intended disease uses.

    section 502(f)(1) [21 U.S.C. 352(f)(1)]
  4. FDA said introducing these misbranded drugs into interstate commerce violates the Act.

    section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks Chambers' Apothecary to notify it in writing within 15 working days of the specific steps taken to address the violations, with an explanation and supporting documents. If the company cannot complete corrections in that time, FDA asks it to state the reason and the date it will finish.

Who should pay attention

  • dietary supplement companies making disease claims
  • retailers and online marketplaces selling supplements
  • brands selling blood pressure or CoQ10 products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk